Body Vision Medical, a leader in artificial intelligence (AI)-powered intraoperative imaging, has announcde that its LungVision advanced imaging platform has received Pre-Market Approval from Singapore's Health Sciences Authority (HSA).
This clearance enables full commercialisation of LungVision in Singapore and represents a significant milestone in the company's ongoing mission to improve early and accurate diagnosis of lung cancer worldwide.
Lung cancer is a significant health concern in Singapore, ranking as the second most common cancer in men and the third most common in women. Over a five-year period (2018-2022), approximately 9,000 cases were diagnosed. According to the Singapore Cancer Registry, most patients are diagnosed at a late stage, reducing the effectiveness of treatment and survival rates. Improving early diagnosis with advanced imaging technology can have a meaningful impact on patient outcomes.
LungVision transforms any standard two-dimensional fluoroscopic imaging system into an AI-powered 3D imaging system, giving physicians real-time navigation and enhanced visualization to perform more precise bronchoscopic biopsies. The technology supports earlier and more accurate diagnoses of pulmonary nodules—helping improve patient outcomes while keeping procedural costs low.
